SANA
HealthcareSana Biotechnology, Inc. · Biotechnology · $850M
What is Sana Biotechnology, Inc.?
Sana Biotechnology is a clinical-stage biotech company headquartered in Seattle, Washington, focused on engineering cells as medicines. Its platform spans both ex vivo and in vivo approaches across multiple serious disease areas.
Sana develops engineered cell therapies designed to treat diseases where conventional medicines fall short. The company operates two core platforms: ex vivo engineering, where cells are modified outside the body before being administered, and in vivo engineering, which aims to reprogram cells directly inside a patient. Revenue is not yet generated from commercial products — the company funds operations through capital markets while advancing a pipeline spanning oncology, diabetes, neurological disorders, cardiovascular disease, and genetic conditions.
Sana Biotechnology was incorporated in 2018 and is headquartered in Seattle, Washington.
- Allogeneic CAR-T cell therapies targeting blood cancers including leukemia and lymphoma
- In vivo cell engineering candidates for type 1 diabetes and multiple sclerosis
- Gene-correction programs for rare genetic disorders such as sickle cell disease
- Pipeline candidates addressing multiple myeloma via CD38-targeted approaches
- CNS-focused programs for Pelizaeus-Merzbacher disease and Huntington's disease
Is SANA a Good Stock to Buy?
UQS Score rates SANA as Poor overall, reflecting the early-stage nature of its business and the significant uncertainties that come with a pre-commercial biotech.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's balance sheet and near-term financial structure are not in immediate distress, which is meaningful for a clinical-stage company burning cash to fund trials.
Quality, Moat, and Growth all register as Weak, consistent with a company that has no commercial revenue, no established competitive advantage, and a pipeline still years from potential approval. Valuation is rated Elevated, meaning the market is pricing in significant future success.
See the exact pillar breakdown and full financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does SANA pay dividends?
No — Sana Biotechnology, Inc. does not currently pay a dividend.
Sana Biotechnology does not pay a dividend, which is standard for clinical-stage biotechs. All available capital is directed toward research, clinical trials, and platform development. Investors in SANA are accepting near-term losses in exchange for potential long-term upside if pipeline candidates reach commercialization.
When does SANA report earnings?
Sana Biotechnology reports financial results on a quarterly cadence, typical for US-listed companies.
As a pre-revenue company, quarterly reports focus on cash runway, operating expenses, and clinical trial progress rather than sales or profit metrics. Pipeline milestones and trial readouts tend to move the stock more than earnings beats or misses in the traditional sense.
For the most recent quarter's results and management commentary, visit Sana Biotechnology's investor relations page.
SANA Price History
-82.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Sana Biotechnology, Inc.?
Based on Sana Biotechnology, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
SANA Long-term Outlook
The fundamental outlook for SANA is shaped by its Weak Growth pillar and Elevated Valuation — a combination that signals the stock is priced for outcomes that remain highly uncertain. Clinical trial results will be the primary catalyst in either direction. The Good Risk pillar provides some reassurance that the company is not in immediate financial jeopardy, but the path to value creation depends entirely on pipeline execution over a multi-year horizon.
Growth drivers
- Positive clinical data from allogeneic CAR-T or in vivo cell engineering programs
- Potential partnership or licensing deals that validate the platform and extend cash runway
- Expanding addressable markets across oncology, rare disease, and autoimmune indications
Key risks
- Clinical trial failures or safety signals that could halt lead programs
- Elevated valuation leaves little margin for setbacks or delays
- Ongoing cash consumption with no commercial revenue to offset operating losses
SANA vs Peers
Sana operates in a competitive cell and gene therapy landscape alongside companies pursuing differentiated biological platforms.
Maravai focuses on life science tools and reagents that support biologic drug development, giving it a more infrastructure-oriented business model compared to Sana's direct therapeutic pipeline.
Janux develops T cell engager bispecific antibodies rather than cell therapies, representing a distinct molecular approach to targeting cancer.
Xencor engineers antibody-based medicines and has a broader set of partnered programs, providing a different risk and revenue profile relative to Sana's fully internal pipeline.
Frequently Asked Questions
What does Sana Biotechnology do?
Sana Biotechnology develops engineered cell therapies for serious diseases. The company uses two platforms — ex vivo (cells modified outside the body) and in vivo (cells reprogrammed inside the patient) — to build treatments for cancer, diabetes, neurological disorders, and rare genetic conditions.
Does SANA pay dividends?
No, Sana Biotechnology does not pay a dividend. As a clinical-stage company with no commercial revenue, all capital is reinvested into research and clinical development. Dividend payments are not typical for pre-revenue biotechs at this stage.
When does SANA report earnings?
Sana reports on a standard quarterly schedule. Because the company has no product revenue, reports center on cash position, trial updates, and operating expenses. Check Sana Biotechnology's investor relations page for the most current schedule and recent filings.
Is SANA a good stock to buy?
UQS Score rates SANA as Poor overall. The Quality, Moat, and Growth pillars are all Weak, and Valuation is Elevated. The Risk pillar is the relative strength. Whether SANA fits a portfolio depends on an investor's tolerance for clinical-stage biotech risk and long time horizons.
Is SANA overvalued?
The UQS Valuation pillar for SANA is rated Elevated, suggesting the current market price reflects optimistic assumptions about pipeline success. For a company with no commercial revenue, valuation is driven by probability-weighted expectations of future approvals rather than current fundamentals.
How does SANA compare to its competitors?
Sana's closest peers in the biotech space — including Janux Therapeutics and Xencor — each pursue different biological strategies for treating cancer and other diseases. Maravai LifeSciences operates more as a tools provider. The full UQS comparison across pillars is available to Pro members.
What is SANA's market cap bracket?
SANA is classified as a small-cap stock. This reflects its early-stage status and the fact that its valuation is based almost entirely on pipeline potential rather than current revenues or earnings.
Who founded Sana Biotechnology?
Sana Biotechnology was originally incorporated as FD Therapeutics, Inc. and renamed in September 2018. The company was founded by a team with roots in cell and gene therapy research. Founding details are publicly available through SEC filings and the company's official history.
Is SANA a long-term quality investment?
As a long-term quality indicator, the UQS Score rates SANA as Poor — driven by Weak scores across Quality, Moat, and Growth. Long-term quality typically requires durable competitive advantages and financial strength, neither of which Sana has established yet. The pipeline could change that picture, but the current profile carries substantial uncertainty.
What is the main competitive advantage of Sana Biotechnology?
Sana's potential advantage lies in its dual-platform approach — combining ex vivo and in vivo cell engineering — which could allow it to address a broader range of diseases than single-platform peers. However, the UQS Moat pillar is currently rated Weak, reflecting that this advantage is not yet commercially proven.
What sector does SANA belong to?
Sana Biotechnology operates in the Healthcare sector, specifically within biotechnology. It sits in the clinical-stage subsegment, meaning it has no approved products and generates no product revenue while advancing its pipeline through trials.
Is SANA a growth stock or value stock?
Based on UQS pillar labels, SANA is neither a traditional growth nor value stock in the conventional sense. Its Growth pillar is Weak and its Valuation pillar is Elevated — a combination more consistent with a speculative clinical-stage bet than a quality growth or value opportunity.
Unlock Full SANA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the exact UQS Score and all five pillar breakdowns
- ✓Access detailed financial metrics and trend data
- ✓Compare SANA side-by-side with biotech peers
- ✓Screen for higher-quality healthcare stocks using UQS filters
- ✓Get the complete analyst-style view available to Pro members
Pro Analysis
SANA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 22, 2026 | 15.6 | 0.0 | 13.0 | 9.9 | 69.3 | 0.0 | -0.5 |
| Apr 14, 2026 | 16.1 | 0.0 | 13.0 | 12.4 | 69.3 | 0.0 | -9.3 |
| Apr 13, 2026 | 25.4 | 0.0 | 50.0 | 12.4 | 69.3 | 0.0 | +9.3 |
| Apr 2, 2026 | 16.1 | 0.0 | 13.0 | 12.4 | 69.3 | 0.0 | — |
SANA — Pillar Breakdown
Quality
— 0.0/100 (25%)Sana Biotechnology, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 9.9/100 (20%)Sana Biotechnology, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 54.2/100 (15%)Sana Biotechnology, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Sana Biotechnology, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)Sana Biotechnology, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for SANA.
Score Composition
Financial Data
More Stock Analysis
How is the SANA UQS Score Calculated?
The UQS (Unified Quality Score) for Sana Biotechnology, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Sana Biotechnology, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Sana Biotechnology, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.